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ABSTRACT
Objectives To investigate whether an authorship effect 
is found that leads to better performance in studies 
conducted by the original developers of the Patient Health 
Questionnaire (PHQ-9) (allegiant studies).
Design Systematic review with random effects bivariate 
diagnostic meta-analysis. Search strategies included 
electronic databases, examination of reference lists and 
forward citation searches.
Inclusion criteria Included studies provided suficient 
data to calculate the diagnostic accuracy of the PHQ-9 
against a gold standard diagnosis of major depression 
using the algorithm or the summed item scoring method at 
cut-off point 10.
Data extraction Descriptive information, methodological 
quality criteria and 2×2 contingency tables.
Results Seven allegiant and 20 independent studies 
reported the diagnostic performance of the PHQ-9 using 
the algorithm scoring method. Pooled diagnostic OR 
(DOR) for the allegiant group was 64.40, and 15.05 for 
non-allegiant studies group. The allegiance status was a 
signiicant predictor of DOR variation (p<0.0001). Five 
allegiant studies and 26 non-allegiant studies reported 
the performance of the PHQ-9 at recommended cut-off 
point of 10. Pooled DOR for the allegiant group was 49.31, 
and 24.96 for the non-allegiant studies. The allegiance 
status was a signiicant predictor of DOR variation 
(p=0.015). Some potential alternative explanations for 
the observed authorship effect including differences in 
study characteristics and quality were found, although it 
is not clear how some of them account for the observed 
differences.
Conclusions Allegiant studies reported better 
performance of the PHQ-9. Allegiance status was 
predictive of variation in the DOR. Based on the observed 
differences between independent and non-independent 
studies, we were unable to conclude or exclude that 
allegiance effects are present in studies examining the 
diagnostic performance of the PHQ-9. This study highlights 
the need for future meta-analyses of diagnostic validation 
studies of psychological measures to evaluate the impact 
of researcher allegiance in the primary studies.
Research on allegiance effects has a long 
tradition in psychotherapy research. In this 
context, allegiance describes the phenomenon 
that researchers and clinicians who devel-
oped a treatment approach or are for other 
reasons invested in it tend to find larger effect 
sizes in favour of their treatment than for 
comparison groups.1 This finding has been 
extensively replicated2 3 and is also robust 
when the quality of research is controlled for. 
Researcher allegiance is subject of ongoing 
debates about the design of efficacy studies as 
well as implications for policy.2 4 5 Researcher 
allegiance is also discussed widely in the liter-
ature on experimental as well as evaluation 
research.6 Since the motivational underpin-
nings of allegiance effects are potentially far 
more ingrained into human behaviour and 
decision making than previously thought,7 
they may occur commonly in clinical research 
in general.
Although it has been suggested that alle-
giance effects may play a role in the validation 
of psychological screening and case-finding 
tools (eg, O'Shea et al., in press), systematic 
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Strengths and limitations of this study
 Ź An original study—the irst meta-analysis of 
diagnostic validation studies of psychological 
measures to evaluate the impact of researcher 
allegiance.
 Ź Using rigorous methodology—strict inclusion/
exclusion and quality assessment criteria.
 Ź We found that the allegiance effect was a signiicant 
predictor of the variation of the diagnostic OR in the 
meta-regression analysis.
 Ź Substantial variability observed in methodological 
quality of included studies.
 Ź Based on the observed methodological differences 
between the independent and non-independent 
studies, we were unable to conclude or exclude that 
allegiance effects are present in studies examining 
the diagnostic performance of the Patient Health 
Questionnaire (PHQ-9).
group.bmj.com on October 6, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Manea L, et al. BMJ Open 2017;7:e015247. doi:10.1136/bmjopen-2016-015247
Open Access 
evaluations of this hypothesis are rare and studies that 
acknowledge potential allegiance effects in such studies 
mainly come from forensic psychology and psychiatry 
backgrounds.8–11 Diagnostic validation studies are geared 
at establishing the sensitivity and specificity of a screening 
or case-finding tool, which is used in practice to differ-
entiate cases from non-cases or to decide about whether 
further assessment or treatment is indicated or will be 
offered. An allegiance effect in such studies would be 
seen in systematically higher sensitivities or specificities 
if the original author(s) is (are) part of the team of such 
a study. Such a bias would have a deleterious affect on 
practice through promising overoptimistic accuracy of 
the screening or case-finding tool or in evaluating the 
cost-effectiveness of the measure in a screening or case-
finding context.
The depression module of the Patient Health Ques-
tionnaire (PHQ-9) is a widely used depression-screening 
instrument in non-psychiatric settings. The PHQ-9 was 
developed by a team of researchers, with its development 
underwritten by an educational grant from Pfizer US Phar-
maceuticals.12 The PHQ-9 can be scored using different 
methods, including an algorithm based on Diagnostic and 
Statistical Manual of Mental Disorders (DSM)-IV criteria 
and a cut-off based on summed-item scores. The psycho-
metric properties of these two approaches have been 
summarised in two recently published meta-analyses.13 14 
The goal of the current review is to investigate, based on 
an established database of PHQ-9 diagnostic validation 
studies,13 14 whether an allegiance effect is found that 
leads to an increased sensitivity and specificity in studies 
that were conducted by researchers closely connected to 
the original developers of the instrument.
METHODS
Study selection
Similar search strategies were used in both systematic 
reviews (for full details, please see Manea et al and Mori-
arty et al13 14). Embase, Medline and PsycINFO were 
searched from 1999 (when the PHQ-9 was first devel-
oped) to August 2013 and September 2013, respectively, 
using the terms ‘PHQ-9’, ‘PHQ’, ‘PHQ$’ and ‘patient 
health questionnaire’. The search strategy is presented 
in online supplementary appendix 1. The reference lists 
of studies fitting the inclusion criteria were manually 
searched and a reverse citation search in Web of Science 
was performed. The authors of unpublished studies were 
contacted and conference abstracts were reviewed in an 
attempt to minimise publication bias.
The following inclusion-exclusion criteria were used:
Population: adult population. Instrument: studies that 
used the PHQ-9. Comparison (reference standard): the accu-
racy of the PHQ-9 had to be assessed against a recognised 
gold-standard instrument for the diagnosis of either DSM 
or International Classification of Disease (ICD) criteria for 
major depression. Studies were included if the diagnoses 
were made using a standardised diagnostic structured 
interview schedule (eg, Mini International Neuropsychi-
atric Interview (MINI), Structured Clinical Interview for 
DSM Disorders (SCID)). Unguided clinician diagnoses 
with no reference to a standard structured diagnostic 
schedule or comparisons of the PHQ-9 with other self-re-
port measures were excluded. Studies were also excluded 
if the target diagnosis was not major depressive disorder 
(MDD, eg, any depressive disorder). Outcome: studies had 
to report sufficient information to calculate a 2×2 contin-
gency table for the algorithm or the recommended cut-off 
point 10. Study design: any design. Additional criterion: we 
avoided double counting of evidence by ensuring that 
only one study of those that reported overlapping data-
sets in different journals were included in the meta-anal-
ysis. Citations with overlapping samples were examined 
to establish whether they contained information relevant 
to the research question that was not contained in the 
included report.
Quality assessment
Quality assessment was performed using the Quality 
Assessment of Diagnostic Accuracy Studies (Revised) 
(QUADAS-2) tool, a tool for evaluating the risk of bias 
and applicability of primary diagnostic accuracy studies 
when conducting diagnostic systematic reviews.15 It covers 
the areas of patient selection, index test, reference stan-
dard and flow and timing.16 This tool was adapted for the 
two reviews and quality assessments were carried out by 
two independent reviewers for all studies included in the 
reviews.
Data synthesis and statistical analysis
We constructed 2×2 tables for cut-off point 1014 and the 
algorithm scoring method.13 Pooled estimates of sensi-
tivity, specificity, positive/negative likelihood ratios and 
diagnostic ORs (DOR) were calculated using random 
effects bivariate meta-analysis.17 Heterogeneity was 
assessed using I2 for the DOR, an estimate of the propor-
tion of study variability that is due to between-study vari-
ability rather than sampling error. We considered values 
of ≥50% to indicate substantial heterogeneity.18 Summary 
receiver operating characteristic curves (sROC) were 
constructed using the bivariate model to produce a 95% 
confidence ellipse within ROC space.19 Each data point 
in the sROC space represents a separate study, unlike a 
traditional ROC plot, which explores the effect varying 
thresholds on sensitivity and specificity in a single study.
We undertook a meta-regression analysis of logit DOR 
using research allegiance as covariate in the meta-regres-
sion model.20 21 Analyses were conducted using STATA 
V.12, with the metan, metandi and metareg user-written 
commands.
Allegiance rating
We rated authorship on a paper if any of the developers 
of the PHQ-9—Kurt Kroenke, MD, Robert L Spitzer, 
MD and Janet BW Williams—as an indicator of poten-
tial allegiance. We also rated as evidence of allegiance as 
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acknowledged collaborations with the developers of the 
PHQ-9, even if they were not listed as coauthors or if the 
authors acknowledged funding from Pfizer to conduct 
the study.
RESULTS
Overview of included studies
Thirty-one studies reported the diagnostic properties of 
the PHQ-9 at cut-off point 10 or above and were included 
in this analysis.14 Twenty-seven studies were included in 
the algorithm review.13 The study selection flow charts can 
be found in online supplementary appendix 2 (figures 1 
and 2). The characteristics of these studies are reported 
in tables 1 and 2 and the results of the methodological 
assessment are presented in tables 3 and 4.
Algorithm scoring method
Descriptive characteristics
The descriptive characteristics of the included studies 
are presented in table 1. Seven individual studies that 
reported the diagnostic performance of the PHQ-9 
using the algorithm scoring method were coauthored 
by the original developers of the PHQ-9,22–26 specifically 
acknowledged one of the developers and support by an 
educational grant from Pfizer USA,27 or were coauthored 
by the first author of a previous study that had also been 
coauthored by one of the developers.28 Twenty non-alle-
giant studies reported the diagnostic properties of the 
PHQ-9 using the algorithm scoring method.
Three (43%, 3/7) of the allegiant studies were 
conducted exclusively in hospital settings.22 26 28 The 
remaining four studies (67%, 4/7) were conducted in 
different settings or non-exclusively hospital settings: one 
in primary care25 and three in mixed settings: psycho-
somatic walk in clinics and family practices23,i outpa-
tient clinics and family practices24 and primary care and 
hospital settings.27 In the non-allegiant group, 13 (65%, 
13/20) studies were conducted in hospital settings.29–41 
Of the remaining seven studies, six were conducted 
in primary care settings42–47 and one in a community 
sample.48
In both groups (non-allegiant and allegiant studies), 
the majority of studies validated a translated version 
of the PHQ-9. Two of the studies authored by devel-
opers (28%, 2/7),25 26 and eight (40%, 8/20) allegiant 
studies29 30 37–40 42 48 were conducted in English.
The mean prevalence of MDD in the group of allegiant 
studies was 13.4% (range 6.1%–29.2%); in the non-alle-
giant group it was 15.5% (range 3.9%–32.4%). The mean 
age of patients in the PHQ-9 developers group was 45.7; all 
but one study had a mean age in the range of 40–50 years. 
In the non-allegiant group, the mean age was 54.6 (range 
i  This study provided separate estimates for the two settings in which it 
was conducted; therefore separate psychometric estimates were gener-
ated for each sample for both algorithm scoring method and summed 
items scoring method at cut-off point 10 (see below).
29.3–75.0), with almost half (8) of the studies reporting 
a mean age of over 60. The percentage of females in the 
PHQ-9 developers was 56.8% (range 28.6%–67.8%) and 
in the non-allegiant group was 59.1 (18%–100%).
All allegiant studies used a self-reported PHQ-9, whereas 
in seven non-allegiant studies (30%, 6/20) the PHQ-9 
was administered by a researcher.30–33 43 48 Apart from 
Muramatsu et al., all allegiant studies used the SCID as 
a gold standard27; the non-allegiant studies used a wider 
range of gold standards including SCAN, CIDI, MINI and 
C-DIS, although the SCID was also frequently used by the 
independent studies as well (45%, 9/20 studies).
Four out of the seven allegiant studies (57%) did not 
include a conflict of interest statement.22 23 25 27 Also, four 
(57%) of the allegiant studies acknowledged funding 
from Pfizer.23–25 27 Only one study27 acknowledged the 
collaboration with one of the developers of the PHQ-9.
Of the non-allegiant studies, 12 (60%) did not include 
a conflict of interest statement.29–32 35–37 39 44–46 48 It appears 
that newer studies were more likely to include a conflict 
of interest statement, which may reflect a recent change 
in reporting. Funding was acknowledged by most studies 
(18/20) and most received funding from academic or/
and health research institutions. Two studies received 
funding from pharmaceutical companies—Lundbeck43 
and Pfizer35 and one study acknowledged that Pfizer 
Italia provided the Italian version of PHQ-9 and gave the 
authors permission to use it.36
Diagnostic test accuracy
Pooled sensitivity and specificity was calculated separately 
for the non-allegiant and allegiant studies. Pooled sensi-
tivity for the allegiant studies of the PHQ-9 was 0.77 (95% 
CI 0.70 to 0.84), pooled specificity was 0.94 (95% CI 0.90 
to 0.97) and the pooled DOR was 64.40 (95% CI 34.15 
to 121.43). Heterogeneity was high (I²=78.9%). Figure 1 
represents the sROCs for this set of studies.
Pooled sensitivity for the non-allegiant studies was lower 
compared with the developer authored studies group at 
0.48 (95% CI 0.41 to 0.91), pooled specificity was the 
same at 0.94 (95% CI 0.91 to 0.95). The pooled DOR was 
approximately four times lower at 15.05 (95% CI 11.03 
to 20.52) (see figure 1). Heterogeneity was substantial at 
I²=68.1%.
The meta-regression analysis for algorithm studies with 
non-allegiant status as the predictor of the DOR showed 
that non-allegiant status was a significant predictor of the 
DOR (p<0.0001) and explained a substantial amount of 
the observed heterogeneity (51.5%).
Quality assessment
The results of the quality assessment using QUADAS-2 
are given in table 3 for the studies reporting on the diag-
nostic performance of the algorithm scoring method. In 
the patient selection domain, more non-allegiant studies 
(65%, 13/20) than allegiant (29%, 2/7) met the criterion 
for consecutive referrals. There were no marked differ-
ences on the other two criteria in this domain (avoid 
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Table 1 Descriptive characteristics of algorithm studies13
Study
Sample characteristics
Sample size and % 
depressed
PHQ-9 
characteristics
Diagnostic 
standard
a) COI declaration
b) Funding
c) Relationship with original developers(country, setting, age, sex)
Diez-Quevedo et 
al22 
Country: Spain
Setting: medical and surgical tertiary 
hospitals
Age (years): M=43 (SD=14.2)
Female: 45.6%
n=1003
Depressed: 8.2%
Administration: self-
report
Language: Spanish
DSM-III-R
SCID
a) No COI declaration
b) Funding acknowledged (academic institutions)
c) Not acknowledged
Gräfe et al23 Country: Germany
Setting: psychosomatic walk-in clinics and 
family practices
Age (years): male=41.9 (SD=13.8)
Female: 67.8%
n=528
Depressed: 29.2% 
psychosomatic 
patients; 6.16% 
medical patients
Language: German
Administration: self-
report
DSM-IV
SCID
a) No COI declaration
b) Acknowledged funding from Pizer
c) Not acknowledged
Lowe et al24 Country: Germany
Setting: outpatient clinics and family 
practices
Age (years): male=41.7 (SD=13.8)
Female: 67.1%
n=501
Depressed: 13.2%
Administration: self-
report
Language: German
DSM–IV
SCID
a) COI declaration ‘This study was supported by unrestricted 
restricted grants from Pizer Germany and from the medical faculty 
of the University of Heidelberg Germany, and there are no COI’.
b) Acknowledged funding from Pizer and academic institution
c) Not acknowledged
Muramatsu et al27 Country: Japan
Setting: primary care and general hospital
Age (years): male=43.3 (SD=16.4)
Female: 59.5%
n=131
Depressed: 28.2%
Administration: self-
report
Language: Japanese
DSM–IV
MINI
a) No COI declaration
b) Acknowledged funding from Pizer
c) Acknowledged one of the developers of the PHQ-9: ‘The 
authors acknowledge Dr RL Spitzer’
Navinés et al28 Country: Spain
Setting: general hospital (patients with 
chronic HCV)
Age (years): male=43.4 (SD=10.2)
Female: 28.6%
n=500
Depressed: 6.4%
Administration: self-
report
Language: Spanish
DSM–IV
SCID
a) All authors declared that they had no COI.
b) Role of funding source declared
c) Not acknowledged
Spitzer et al25 Country: USA
Setting: primary care
Age (years): male=46 (SD=17.2)
Female: 66%
n=3000 (585 received 
SCID)
Depressed: 10%
Administration: self-
report
Language: English
DSM-III-R
SCID
a) No COI declaration
b) Acknowledged funding from Pizer. ‘Drs Spitzer and Williams 
receive honoraria and consulting money from Pizer, which has 
supported this work’.
c) N/A
Thekkumpurath 
et al26
Country: UK
Setting: hospital (cancer patients)
Age (years): male=61
Female: 63%
n=782
Depressed: 6.3% (of 
the whole sample)
Administration: not 
stated
Language: English
DSM-IV
SCID
a) COI declaration: ‘Supported by Cancer Research UK’
b) As in a)
c) Not acknowledged
Ayalon et al43 Country: Israel
Age (years): male=75 (SD=8.1)
Female: 40.5%
n=153
Depressed: 3.9%
Administration: 
researcher 
administered
Language: Hebrew
DSM-IV
SCID
a) COI declaration: ‘The project was funded by an Investigator’s 
Initiated Research Grant from Lundbeck International given to 
Dr Liat Ayalon. Lundbeck International had no other involvement 
in the project concept of design or in this paper. Per Bech has 
occasionally over the past 3 years until August 2008 received 
funding from and has been speaker or member of advisory 
boards for pharmaceutical companies with an interest in the drug 
treatment of affective disorders (AstraZeneca, Lilly, H Lundbeck 
A/S, Lundbeck Foundation and Organon)'.
b) Acknowledged funding from Lundbeck International
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Study
Sample characteristics
Sample size and % 
depressed
PHQ-9 
characteristics
Diagnostic 
standard
a) COI declaration
b) Funding
c) Relationship with original developers(country, setting, age, sex)
Eack et al29 Country: USA
Setting: community mental health centres 
for children
Age (years): male=39.20 (SD 9.63)
Female: 100%
n=50
Depressed: 28%
Administration: self-
report
Language: English
DSM-IV
SCID
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Fann et al30 Country: USA
Setting: trauma hospital (inpatients with 
traumatic brain injury)
Age (years): male=42 (SD=17.9)
Female: 29.1%
n=135
Depressed: 16.3%
Administration: 
telephone-
administered
Language: English
DSM-IV
SCID
a) No COI declaration
b) Funding acknowledged (academic institutions)
Gelaye et al31 Country: Ethiopia
Setting: general hospital
Age (years): 34.9 (SD=11.6)
Female: 63.1%
n=363
Depressed: 12.6%
Administration: 
researcher-
administered
Language: Amharic
DSM-IV
SCAN
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Gjerdingen et al48 Country: USA
Setting: community
Age (years): male=29.3
Female: 100%
n=438
Depressed: 4.6%
Administration: 
telephone or self-
report
Language: English
DSM-IV
SCID
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Henkel et al44 Country: Germany
Setting: primary care
Age (years): not reported
Female: 74%
n=448
Depressed: 10%
Administration: self-
report
Language: German
DSM-IV
CIDI
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Hyphantis et al32 Country: Greece
Setting: hospital – rheumatology patients
Age (years): male=54.2 (SD=13.5)
Female: 74%
n=213
Depressed: 32.4%
Administration: 
researcher 
administered
Language: Greek
DSM-IV
MINI
a) No COI declaration
b) No funding acknowledgement
Inagaki et al33 Country: Japan
Setting: general hospital
Age whole sample (years): male=73.5 
(SD=12.3)
Female: 59.3%
n=104 out of 511 
received MINI
Depressed: 7.4%
Administration: 
researcher 
administered
Language: Japanese
DSM-IV
MINI
a) COI declaration: ‘The authors declare that they have no 
competing interests’. b) Funding acknowledged (academic/
health research institutions)
Khamseh et al34 Country: Iran
Setting: diabetes clinic
Age (years): male=56.17 (SD=9.60)
Female: 51.9%
n=185
Depressed: 43.2%
Administration:self 
report
Language: Persian
DSM-IV
SCID
a) COI declaration: the authors declared no competing interests
b) Funding acknowledged (academic/health research institutions)
Lamers et al45 Country: The Netherlands
Setting: primary care (elderly)
Age (years): male=71.4 (SD=6.90)
Female: 48.2%
n=713
Depressed: 10.7%
Administration:self 
report
Language: Dutch
DSM-IV
MINI
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Table 1 Continued 
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 Study
Sample characteristics
Sample size and % 
depressed
PHQ-9 
characteristics
Diagnostic 
standard
a) COI declaration
b) Funding
c) Relationship with original developers(country, setting, age, sex)
Lotrakul et al46 Country: Thailand
Setting: primary care
Age (years): male=45.0 (SD=14.30)
Female: 73.7%
n=279
Depressed: 6.8%
Administration:self 
report
Language: Thai
DSM-IV
MINI
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Persoons et al35 Country: Belgium
Setting: hospital (otolaryngology patients)
Age (years): male=48.2 (SD=12.9)
Female: 65.6%
n=268 (97 received 
MINI)
Depressed: 16.5%
Administration: self-
report
Language: Dutch
DSM-IV
MINI
a) No COI declaration
b) Funding acknowledged (academic/health research institutions) 
and Pizer Belgium
Picardi et al36 Country: Italy
Setting: hospital (dermatology inpatients)
Age (years): male=37.5
Female: 56%
n=141
Depressed: 8.5%
Administration: self-
report
Language: Italian
DSM-IV
SCID
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Acknowledged Pizer Italia SRL for providing the Italian version of 
the PHQ-9 and for permission to use it.
Stafford et al37 Country: Australia
Setting: hospital (cardiology patients)
Age (years): male=64.1 (SD=10.3)
Female: 66%
n=193
Depressed: 18%
Administration: self-
report
Language: English
DSM-IV
MINI
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Thombs et al38 Country: USA
Setting: hospital (outpatients with coronary 
heart disease)
Age (years): male=67 (SD=11)
Female: 18%
n=1024
Depressed: 22%
Administration: not 
stated
Language: English
DSM
C-DIS
a) COI declaration ‘None disclosed’
b) Funding acknowledged (academic/health research institutions)
Thompson et al39 Country: USA
Setting: patients with Parkinson's disease
Age (years): 72.5 (SD=9.6)
Female: 42%
n=214
Depressed: 14%
Administration:self 
administered
Language: English
DSM-IV
SCID
a) No COI declaration
b) Funding acknowledged (academic/health research institutions)
Turner et al40 Country: Australia
Setting: stroke patients
Age (years): 66.7 (SD=13.1)
Female: 47.2%
n=72
Depressed: 18%
Administration:self 
administered
Language: English
DSM-IV
SCID
a) COI declaration: disclosures ‘none’.
b) Funding acknowledged (academic/health research institutions)
van Steenbergen-
Weijenburg et al41
Country: The Netherlands
Setting: patients with diabetes 
Age (years): male=61.8 (SD=13.6)
Female: 48.7%
n=197
Depressed: 18.8%
Administration: self 
administered
Language: Dutch
DSM-IV
SCID
a) COI declaration: ‘The authors declare that they have no 
competing interests’.
b) Funding acknowledged (academic/health research 
institutions)—‘this had no inluence on the content of this article’.
Zuitthoff et al47 Country: The Netherlands
Setting: primary care
Age (years): male=51 (SD=16.7)
Female: 63%
n=1338
Depressed: 13%
Administration: self-
report
Language: Dutch
DSM-IV
CIDI
a) COI declaration ‘The authors declare that they have no 
competing interests’.
b) Funding acknowledged (academic/health research institutions)
CIDI, Composite International Diagnostic Interview,CIS-R, Clinical Interview Schedule;COI, conlict of interest; DSM, Diagnostic and Statistical Manual of Mental Disorders; MINI, Mini-
International Neuropsychiatric Interview; N/A, not available; SCAN, Schedules for Clinical Assessments in Neuropsychiatry; SCID, Structured Clinical Interview for DSM Disorders.
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Table 2 Descriptive characteristics of the summed items scoring method studies cut-off point 1014
Study Sample characteristics
Sample size and % 
MDD PHQ-9 characteristics
Diagnostic 
standard
a) COI declaration
b) Funding
c) Relationship with original developers
13. Gräfe et al23 Country: Germany
Setting: psychosomatic walk-in clinics and 
family practices
Mean age: 41.9 (SD=13.8)
Female: 67.8%
n=528
Depressed: 29.2% 
psychosomatic 
patients; 6.16% 
medical patients
Administration: self-report
Language: German
Cut-offs: 10–14
DSM-IV
SCID
a) No COI declaration
b) Acknowledged funding from Pizer
c) Not acknowledged
16. Kroenke et al12 Country: USA
Setting: primary care
Mean age: 46 (SD=17)
Female: 66%
n=580
7.1% MDD
Administration: self-report
Language: English
Cut-offs: 9–15
DSM-IV 
SCID
a) No COI declaration
b) Acknowledged funding from Pizer
c) N/A
22. Navinés et al28 Country: Spain
Setting: general hospital (patients with 
chronic HCV)
Mean age: 43.4 (SD=10.2)
Female: 28.6%
n=500
6.4% MDD
Administration: self-report
Language: Spanish
Cut-offs: 10
DSM–IV
SCID
a) All authors declared that they had no COI
b) Role of funding source declared
c) Not acknowledged
29. 
Thekkumpurath 
et al26
Country: UK
Setting: hospital (cancer patients)
Mean age: 61
Female: 63%
n=782
6.3% MDD (of the 
whole sample)
Administration: not stated
Language: English
Cut-offs: 5–10
DSM-IV
SCID
a) COI declaration: ‘Supported by Cancer Research UK’
b) As in a)
c) Not acknowledged
33. Williams et al49 Country: USA
Setting: secondary care (poststroke)
Mean age: unclear
Female: unclear
n=316
33.5% MDD
Administration: unclear
Language: English
Cut-offs: 10
DSM-IV 
SCID
a) No COI declaration
b) Funding acknowledged (academic institutions)
c) Not acknowledged
1. Adewuya et al55 Country: Nigeria
Setting: community (students)
Mean age: 24.8 (15–40)
Female: 41.2%
n=512
2.5% MDD
Administration: Self-report
Language: English
Cut-offs: 8–12
DSM-IV MINI a) No COI declaration
b) No funding declaration
2. Arroll et al42 Country: New Zealand
Setting: primary care
Mean age: 49 (17–99)
Female: 61%
n=2642
6.2% MDD
Administration: not stated
Language: English
Cut-offs: 8, 10, 12, 15
DSM-IV 
SCID
a) No COI declaration
b) Funding acknowledged (academic/health research 
institutions)
3. Azah et al62 Country: Malaysia
Setting: primary care
Mean age: 38.7 (18–79)
Female: 61.7%
n=180
16.6% MDD
Administration: self-report
Language: Malay
Cut-offs: 5–12
DSM-IV
CIDI
b) No COI declaration
c) Funding acknowledged (academic/health research 
institutions)
4. Chagas et al50 Country: Brazil
Setting: secondary care
Mean age: not stated
Female: 52.7%
n=84
25.5% MDD
Administration: self-report
Language: Brazilian
Cut-offs: 7–10
DSM-IV 
SCID
a) COI declaration ‘None declared’
b) Funding acknowledged (academic/health research 
institutions)
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Study Sample characteristics
Sample size and % 
MDD PHQ-9 characteristics
Diagnostic 
standard
a) COI declaration
b) Funding
c) Relationship with original developers
6. de Lima Osorio 
et al60 
Country: Brazil
Setting: primary care
Mean age: unclear
Female: 100%
n=177
34% MDD
Administration: research 
assistants
Language: Brazilian 
Portuguese
Cut-offs: 10–15
DSM-IV 
SCID
a) No COI declaration
b) Funding acknowledged (academic institutions)
7. Elderon et al51 Country: USA
Setting: secondary care
Mean age: unclear
Female: 18%
n=1022
18.3% MDD
Administration: self-report
Language: English
Cut-offs: 10
C-DIS a) COI declaration—‘No disclosures’
b) Funding acknowledged (academic institutions and 
industry—AHA Pharmaceuticals Roundtable)—
‘The funding organisations had no role in the design or 
conduct of the study, collection, management, analysis or 
interpretation of data; or preparation, review or approval of 
the manuscript’.
8. Fann et al30 Country: USA
Setting: trauma hospital (inpatients with 
traumatic brain injury)
Mean age: 42 (SD=17.9)
Female: 29.1%
n=135
16.3% MDD
Administration: telephone-
administered
Language: English
Cut-offs: 10
DSM-IV
SCID
a) No COI declaration
b) Funding acknowledged (academic institutions)
9. Fine et al56 Country: USA
Setting: primary care (Ohio Army National 
Guard)
Mean age: 31 (17-60)
Female: 12%
n=498
21.5% MDD
Administration: telephone-
administered
Language: English
Cut-offs: 10, 15
DSM-IV 
SCID-I
a) COI—last author disclosed inancial and consulting 
interests (Pizer not one of them). All other authors 
declared that they have no COI.
b) Funding acknowledged—DoD Medical Research. ‘The 
sponsor had no role in study design, data collection, 
analysis, interpretation of results, report writing or 
manuscript submission'.
10. Gelaye et al31 Country: Ethiopia
Setting: general hospital
Mean age: 34.9 (SD=11.6)
Female: 63.1%
n=363
12.6% MDD
Administration: researcher-
administered
Language: Amharic
Cut-offs: 9–11
DSM-IV
SCAN
a) No COI declaration
b) Funding acknowledged (academic/health research 
institutions)
11. Gilbody et al57 Country: UK
Setting: primary care
Mean age: 42.5 (SD 13.6)
Female: 77%
n=96
37.5 MDD
Administration: not stated
Language: English
Cut-offs: 9–13
DSM-IV 
SCID
a) COI declaration—last author involved in the 
development of one of the instruments (CORE-OM), ‘but 
does not gain inancially from its use.
b) Funding acknowledged (academic/health research 
institutions)
12. Gjerdingen 
et al48
Country: USA
Setting: community
Mean age: 29.3
Female: 100%
n=438
4.6% MDD
Administration: telephone or 
self-report
Language: English
Cut-offs: 10
DSM-IV
SCID
c) No COI declaration
d) Funding acknowledged (academic/health research 
institutions)
14. Hyphantis et 
al32
Country: Greece
Setting: hospital— rheumatology patients
Mean age: 54.2 (SD=13.5)
Female: 74%
n=213
32.4% MDD
Administration: researcher 
administered
Language: Greek
Cut-offs: 4–16
DSM-IV
MINI
a) No COI declaration
b) No funding acknowledgement
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Study Sample characteristics
Sample size and % 
MDD PHQ-9 characteristics
Diagnostic 
standard
a) COI declaration
b) Funding
c) Relationship with original developers
15. Khamseh et 
al34
Country: Iran
Setting: outpatient diabetic clinic
Mean age: 56.1 (SD=9.6)
Female: 51.8%
n=185
43.2% MDD
Administration: self-report
Language: Persian
Cut-offs: 10, 13
DSM-IV 
SCID
a) COI declaration: the authors declared no competing 
interests.
d) Funding acknowledged (academic/health research 
institutions)
19. Liu et al63 Country: Taiwan
Setting: primary care
Mean age: not speciied
Female: 60.9%
n=1532
3.3% MDD
Administration: self-report
Language: Chinese version
Cut-offs: 9–11
SCAN a) No COI declaration
b) Funding acknowledged (academic/health research 
institutions)
20. Lotrakul et al46 Country: Thailand
Setting: primary care
Mean age: 45.0 (SD=14.30)
Female: 73.7%
n=279
6.8% MDD
Administration: self report
Language: Thai
Cut-offs: 7–15
DSM-IV
MINI
a) No COI declaration
d) Funding acknowledged (academic/health research 
institutions)
23. Patel et al61 Country: India
Setting: primary care
Mean age: 37.5 (18–83)
Female: 56.4%
n=299
4.3% MDD
Administration: face-to-face 
interview
Language: not speciied
Cut-offs: 7–15
CIS-R a) COI declaration—No declaration of Interest
b) Funding acknowledged (academic/health research 
institutions)
24. Phelan et al58 Country: USA
Setting: primary care (elderly)
Mean age: 78 (SD=7)
Female: 62%
n=71
12% MDD
Administration: research 
assistant
Language: English
Cut-offs: 8–12
DSM-IV 
SCID
a) COI declaration—no competing interests
b) Funding acknowledged (academic/health research 
institutions). ‘The funder had no role in the study design, 
methods, data collection, analysis or interpretation of 
data, nor any role in the preparation of the manuscript or 
decision to submit the manuscript for publication'.
25. Rooney et al52 Country: UK
Setting: secondary care (glioma)
Mean age: 54.2 (SD=12.3)
Female: 42.6%
n=129
13.5% MDD
Administration: self-report
Language: English
Cut-offs: 8–11
DSM-IV 
SCID
a) COI declaration ‘The authors declare that they have no 
COI’.
b) Funding acknowledged (academic/health research 
institutions)
26. Sherina et al Country: Malaysia
Setting: primary care
Mean age: 30.9 (18–81)
Female: 100%
n=146
21.2% MDD
Administration: self-report
Language: Malay
Cut-offs: 10
CIDI a) COI declaration ‘The authors declare that they have no 
competing interests’.
b) Funding acknowledged (academic/health research 
institutions)
27. Sidebottom 
et al59
Country: USA
Setting: community (prenatal)
Mean age: 23 (SD=5.5)
Female: 100%
n=745
3.6% MDD
Administration: interview
Language: English
Cut-offs: 10
DSM-IV 
SCID
b) COI declaration ‘The authors declare that they have no 
inancial COI’.
b) Funding acknowledged (academic/health research 
institutions)
28. Stafford et al37 Country: Australia
Setting: secondary care (cardiac 
procedures)
Mean age: 64.14 (38–91)
Female: 19.2%
n=193
18.1% MDD
Administration: self-report
Language: English
Cut-offs: 10
DSM-IV MINI a) No COI declaration
b) Funding acknowledged (academic/health research 
institutions)
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Study Sample characteristics
Sample size and % 
MDD PHQ-9 characteristics
Diagnostic 
standard
a) COI declaration
b) Funding
c) Relationship with original developers
30. Thombs et al38 Country: USA
Setting: hospital (outpatients with coronary 
heart disease)
Mean age: 67 (SD=11)
Female: 18%
n=1024
22% MDD
Administration: not stated
Language: English
Cut-offs: 7–10
DSM
C-DIS
a) COI declaration ‘None disclosed’
b) Funding acknowledged (academic/health research 
institutions)
32. Watnick et al53 Country: USA
Setting: secondary care (dialysis)
Mean age: 63 (SD=15)
Female: 32.3%
n=62
19% MDD
Administration: self-report
Language: English
Cut-offs: 10
DSM-IV 
SCID
a) No COI declaration
b) Funding acknowledged (academic/health research 
institutions)
34. Wittkampf et 
al64
Country: The Netherlands
Setting: primary care
Mean age: 49.8
Female: 66.7%
n=664
12.3% MDD
Administration: self-report
Language: not speciied
Cut-offs: 10 and 15
DSM-IV 
SCIDI
a) No COI declaration
b) Funding acknowledged (academic/health research 
institutions)
35. Zhang et al54 Country: Hong Kong
Setting: secondary care (diabetic 
outpatients)
Mean age: 55.1 (SD=9.5)
Female: 40.8%
n=99
23.2% MDD
Administration: self-report
Language: Chinese version
Cut-offs: 15
DSM-IV MINI a) COI declaration—last author acknowledged inancial 
COI. The other authors declare that they have no 
competing interests.
b) Funding acknowledged (academic/health research 
institutions)
36. Zuithoff et al47 Country: The Netherlands
Setting: primary care
Age (years): male=51 (SD=16.7)
Female: 63%
n=1338
Depressed: 13%
Administration: self-report
Language: Dutch
DSM-IV
CIDI
a) COI declaration 'The authors declare that they have no 
competing interests'.
b) Funding acknowledged (academic/health research 
institutions)
COI, conlict of interest; DSM, Diagnostic and Statistical Manual of Mental Disorders; MDD, major depressive disorder; N/A, not available; SCID, Structured Clinical Interview for DSM 
Disorders.
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Table 3 Quality assessment of included studies in the algorithm meta-analysis13 
Study
Patient selection:
Patient 
selection:
Patient 
selection:
Patient 
selection: Index test: Index test: Index test: Index test:
Consecutive or 
random sample
Avoid case-
control/
avoid artiicially 
inlated base 
rate
Avoided 
inappropriate 
exclusions
Overall risk of 
bias
PHQ-9 
interpreted blind 
to reference test
If translated, 
appropriate 
translation
If translated, 
psychometric 
properties 
reported
Overall risk of 
bias
Allegiant studies
Diez-Quevedo et al22 ✗ ✓ ✗ High ? ✓ ✓ Unclear
Gräfe et al23 ✓ ✓ ✓ Low ? ✓ ✓ Unclear
Lowe et al24 ✗ ✓ ✓ High ✓ ✓ ✓ Low
Muramatsu et al27 ? ✓ ? Unclear ✓ ✓ ? Unclear
Navines et al28 ✓ ✓ ✓ Low ✓ ✓ ? Unclear
Spitzer et al25 ✗ ✓ ✓ High ✓ N/A N/A Low
Thekkumpurath et al26 ✗ ✗ ✓ High ✓ N/A N/A Low
Non-allegiant studies
Arroll et al42 ✓ ✓ ✓ Low ✓ N/A N/A Low
Ayalon et al43 ? ✓ ✓ Unclear ? ✓ ? Unclear
Eack et al29 ? ✓ ? Unclear ? N/A N/A Unclear
Fann et al30 ✓ ✗ ✗ High ✓ N/A N/A Low
Gelaye et al31 ? ✗ ? High ✓ ✓ ? Unclear
Gjerdingen et al48 ✓ ✓ ✓ Low ? N/A N/A Unclear
Henkel et al44 ✓ ✓ ✓ Low ? N/A N/A Unclear
Hyphantis et al32 ✓ ✓ ✗ High ✓ ? ? Unclear
Inagaki et al33 ✓ ✗ ✓ High ✓ ? ? Unclear
Khamseh et al34 ✓ ✓ ? Unclear ✓ ✓ ? Unclear
Lamers et al45 ✓ ✗ ✗ High ✓ ? ? Unclear
Lotrakul et al46 ✗ ✓ ? High ✓ ✓ ? Unclear
Persoons et al35 ✓ ✓ ✓ Low ✓ ✓ N/A Low
Picardi et al36 ✓ ✓ ✓ Low ✓ ? ? Unclear
Stafford et al37 ✓ ✓ ✓ Low ✓ N/A N/A Low
Thombs et al38 ✗ ✓ ? Unclear ? N/A N/A Unclear
Thomspon et al39 ? ✓ ✓ Unclear ? N/A N/A Unclear
Turner et al40 ✓ ✓ ✓ Low ✓ N/A N/A Low
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Study
Patient selection:
Patient 
selection:
Patient 
selection:
Patient 
selection: Index test: Index test: Index test: Index test:
Consecutive or 
random sample
Avoid case-
control/
avoid artiicially 
inlated base 
rate
Avoided 
inappropriate 
exclusions
Overall risk of 
bias
PHQ-9 
interpreted blind 
to reference test
If translated, 
appropriate 
translation
If translated, 
psychometric 
properties 
reported
Overall risk of 
bias
van Steenbergen-
Wijenburg et al41
? ✓ ✓ Unclear ? ? ? Unclear
Zuithoff et al47 ✓ ✓ ✓ Low ✓ ✓ ? Unclear
Study
Reference 
test:
Reference 
test:
Reference 
test:
Reference 
test:
Reference 
test: Flow/timing: Flow/timing: Flow/timing: Flow/timing:
Reference 
test correctly 
classiies 
target 
condition
Reference test 
interpreted 
blind to PHQ-9
If translated, 
appropriate 
translation
If translated, 
psychometric 
properties 
reported
Overall risk of 
bias
Interval of 
2 weeks or less
All participants 
receive same 
reference test
All participants 
included in 
analysis?
Overall risk of 
bias
Allegiant studies
Diez-Quevedo et al22 ✓ ✓ ✓ ? Unclear ✓ ✓ ✓ Low
Gräfe et al23 ✓ ? N/A N/A Unclear ✓ ✓ ✓ Low
Lowe et al24 ✓ ✓ N/A N/A Low ✓ ✓ ✓ Low
Muramatsu et al27 ✓ ✓ ✓ ✓ Low ✓ ✓ ? Unclear
Navines et al28 ✓ ✓ ? ? Unclear ✓ ✓ ✓ Low
Spitzer et al25 ✓ ✓ N/A N/A Low ✓ ✓ ✗ High
Thekkumpurath et al26 ✓ ✓ N/A N/A Low ? ✓ ✗ High
Non-allegiant studies
Arroll et al42 ✓ ✓ N/A N/A Low ✓ ✓ ✓ Low
Ayalon et al43 ✓ ? ✓ ? Unclear ? ✓ ✓ Unclear
Eack et al29 ✓ ? N/A N/A Unclear ? ✓ ? Unclear
Fann et al30 ✓ ? N/A N/A Unclear ✓ ✓ ✗ High
Gelaye et al31 ✓ ✓ ✓ ✓ Low ✓ ✓ ✗ High
Gjerdingen et al48 ✓ ? N/A N/A Unclear ✓ ✓ ✗ High
Henkel et al44 ✓ ? N/A N/A Unclear ✓ ✓ ✗ High
Hyphantis et al32 ✓ ✓ ? ? Unclear ✓ ✓ ✗ High
Inagaki et al33 ✓ ✓ ✓ ? Unclear ✓ ✓ ✗ High
Khamseh et al34 ✓ ✓ ✓ ? Unclear ✓ ✓ ? Unclear
Lamers et al45 ✓ ✓ ? ? Unclear ? ✓ ✗ High
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Study
Reference 
test:
Reference 
test:
Reference 
test:
Reference 
test:
Reference 
test: Flow/timing: Flow/timing: Flow/timing: Flow/timing:
Reference 
test correctly 
classiies 
target 
condition
Reference test 
interpreted 
blind to PHQ-9
If translated, 
appropriate 
translation
If translated, 
psychometric 
properties 
reported
Overall risk of 
bias
Interval of 
2 weeks or less
All participants 
receive same 
reference test
All participants 
included in 
analysis?
Overall risk of 
bias
Lotrakul et al46 ✓ ✓ ✓ ✓ Low ? ✓ ✗ High
Persoons et al35 ✓ ✓ ? ? Unclear ✓ ✓ ✓ Low
Picardi et al36 ✓ ✓ ✓ ? Unclear ✓ ✓ ✗ High
Stafford et al37 ✓ ✓ N/A N/A Low ✓ ✓ ✗ High
Thombs et al38 ? ✓ N/A N/A Unclear ✓ ✓ ✓ Low
Thompson et al39 ✓ ? N/A N/A Unclear ✓ ✓ ✗ High
Turner et al40 ✓ ? N/A N/A Unclear ? ✓ ✗ High
van Steenbergen-
Wijenburg et al41
✓ ✗ ? ? High ✓ ✓ ✗ High
Zuithoff et al47 ✓ ✓ ? ? Unclear ? ✓ ✓ Unclear
✓, criterion met; ✗, criterion not met; ?, insuficient information to code whether criterion met; N/A, not applicable; PHQ-9, Patient Health Questionnaire-9.
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Table 4 Quality assessment of included studies in the summed item scoring method cut-off point 10 meta-analysis14
Study
Patient 
selection:
Patient 
selection:
Patient 
selection:
Patient 
selection: Index test: Index test: Index test: Index test: Index test:
Consecutive 
or random 
sample
Avoid case-
control/avoid 
artiicially 
inlated base 
rate
Avoided 
inappropriate 
exclusions
Overall risk of 
bias
PHQ-9 
interpreted 
blind to 
reference test
Was a 
threshold 
prespeciied?
If translated, 
appropriate 
translation
If translated, 
psychometric 
properties 
reported
Overall risk of 
bias
Allegiant studies
13. Gräfe et al23 ✓ ✓ ✓ Low ? ✓ ✓ ✓ Unclear
16. Kroenke et al12 ✓ ✓ ✓ Low ✓ ✓ N/A N/A Low
22. Navinés et al28 ✓ ✓ ✓ Low ✓ ✓ ✓ ? Unclear
29. Thekkumpurath et al26 × × ✓ High ✓ ✓ N/A N/A Low
33. Williams et al49 ✓ ✓ ✓ Low ? ✓ N/A N/A Unclear
Non-allegiant studies
1. Adewuya et al55 ✓ ✓ × Unclear ✓ ✓ N/A N/A Low
2. Arroll et al42 ✓ ✓ ✓ Low ✓ ✓ N/A N/A Low
3. Azah et al62 ✓ × ? High ✓ ✓ ✓ ✓ Low
4. Chagas et al50 ✓ ✓ ✓ Low ✓ ✓ ✓ ✓ Low
6. de Lima Osorio et al60 ✓ × ✓ High ? × N/A N/A High
7. Elderon et al51 ✓ ✓ ✓ Low ✓ ✓ N/A N/A Low
8. Fann et al30 ✓ × × High ✓ ✓ N/A N/A Low
9. Fine et al56 ✓ ✓ ✓ Low ? ✓ N/A N/A Unclear
10. Gelaye et al31 ? × ? High ✓ × ✓ ? High
11. Gilbody et al57 ? ✓ ? Unclear ✓ ✓ N/A N/A Low
12. Gjerdingen et al48 ✓ ✓ ✓ Low ? ✓ N/A N/A Unclear
14. Hyphantis et al32 ✓ × ✓ High ✓ ✓ ? ? Unclear
15. Khamseh et al34 ✓ ✓ ? Unclear ✓ ✓ ✓ ? Unclear
19. Liu et al63 ✓ ✓ ? Unclear ✓ × ✓ ? High
20. Lotrakul et al46 × ✓ ? Unclear ✓ ✓ ✓ ? Unclear
23. Patel et al61 ✓ ✓ ✓ Low ✓ ✓ ? ? Unclear
24. Phelan et al58 × ✓ ✓ High ✓ × N/A N/A High
25. Rooney et al52 ✓ ✓ ✓ Low ? × N/A N/A High
26. Sherina et al ✓ ✓ × High ✓ ✓ ✓ ✓ Low
27. Sidebottom et al59 ✓ ✓ ✓ Low ✓ ✓ N/A N/A Low
28. Stafford et al37 ✓ ✓ ✓ Low ✓ ✓ N/A N/A Low
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Study
Patient 
selection:
Patient 
selection:
Patient 
selection:
Patient 
selection: Index test: Index test: Index test: Index test: Index test:
Consecutive 
or random 
sample
Avoid case-
control/avoid 
artiicially 
inlated base 
rate
Avoided 
inappropriate 
exclusions
Overall risk of 
bias
PHQ-9 
interpreted 
blind to 
reference test
Was a 
threshold 
prespeciied?
If translated, 
appropriate 
translation
If translated, 
psychometric 
properties 
reported
Overall risk of 
bias
30. Thombs et al38 × ✓ ? High ✓ ? N/A N/A Unclear
32. Watnick et al53 ? × ✓ High ✓ ✓ N/A N/A Low
34. Wittkampf et al64 ✓ ✓ ✓ Low ✓ ? N/A N/A Unclear
35. Zhang et al54 ✓ ✓ ? Unclear ? ✓ ? ? Unclear
36. Zuithoff et al47 ✓ ✓ ✓ Low ✓ ✓ ✓ ? Unclear
Study
Reference test: Reference test: Reference test: Reference test:
Reference 
test: Flow / timing: Flow / timing: Flow / timing: Flow / timing:
Reference 
test correctly 
classiies target 
condition
Reference test 
interpreted 
blind to PHQ-9
If translated, 
appropriate 
translation
If translated, 
psychometric 
properties 
reported
Overall risk of 
bias
Interval of 2 
weeks or less
All participants 
receive same 
reference test
All participants 
included in 
analysis?
Overall risk of 
bias
Allegiant studies 
13. Gräfe et al23 ✓ ? N/A N/A Unclear ✓ ✓ ✓ Low
16. Kroenke et al12 ✓ ✓ N/A N/A Low ✓ ✓ ✓ Low
22. Navinés et al28 ✓ ✓ ? ? Unclear ✓ ✓ ✓ Low
29. Thekkumpurath et al26 ✓ ✓ N/A N/A Low ? ✓ ✓ Unclear
33. Williams et al49 ✓ ? N/A N/A Unclear ? ✓ ✓ Unclear
Non-allegiant studies
1. Adewuya et al55 ✓ ✓ N/A N/A Low ✓ ✓ ✓ Low
2. Arroll et al42 ✓ ✓ N/A N/A Low ? ✓ ✓ Unclear
3. Azah et al62 ✓ ✓ ✓ ✓ Low ✓ ✓ × High
4. Chagas et al50 ✓ ✓ ? ? Unclear ✓ ✓ × High
6. de Lima Osorio et al60 ✓ ? N/A N/A Unclear ? ✓ ✓ Unclear
7. Elderon et al51 ✓ ✓ N/A N/A Low ✓ ✓ ✓ Low
8. Fann et al30 ✓ ? N/A N/A Unclear ✓ ✓ × High
9. Fine et al56 ✓ ? N/A N/A Unclear ? ✓ ✓ Unclear
10. Gelaye et al31 ✓ ✓ ✓ ✓ Low ✓ ✓ × High
11. Gilbody et al57 ✓ ✓ N/A N/A Low ? ✓ ✓ Unclear
12. Gjerdingen et al48 ✓ ? N/A N/A Unclear ✓ ✓ × High
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Study
Reference test: Reference test: Reference test: Reference test:
Reference 
test: Flow / timing: Flow / timing: Flow / timing: Flow / timing:
Reference 
test correctly 
classiies target 
condition
Reference test 
interpreted 
blind to PHQ-9
If translated, 
appropriate 
translation
If translated, 
psychometric 
properties 
reported
Overall risk of 
bias
Interval of 2 
weeks or less
All participants 
receive same 
reference test
All participants 
included in 
analysis?
Overall risk of 
bias
14. Hyphantis et al32 ✓ ✓ ? ? Unclear ✓ ✓ × High
15. Khamseh et al34 ✓ ✓ ✓ ? Unclear ✓ ✓ ? Unclear
19. Liu et al63 ✓ ✓ ✓ ✓ Low ✓ ✓ ? Unclear
20. Lotrakul et al46 ✓ ✓ ✓ ✓ Low ? ✓ × High
23. Patel et al61 ✓ ✓ ✓ ? Unclear ? ✓ × High
24. Phelan et al58 ✓ ✓ N/A N/A Low ✓ ✓ ✓ Low
25. Rooney et al52 ✓ ? N/A N/A Unclear ? ✓ × High
26. Sherina et al ✓ ✓ ✓ ✓ Low ✓ ✓ ✓ Low
27. Sidebottom et al59 ✓ ✓ N/A N/A Low ✓ ✓ × High
28. Stafford et al37 ✓ ✓ N/A N/A Low ✓ ✓ × High
30. Thombs et al38 ? ✓ N/A N/A Unclear ✓ ✓ ✓ Low
32. Watnick et al53 ✓ ✓ N/A N/A Low ✓ ✓ ✓ Low
34. Wittkampf et al64 ✓ ✓ N/A N/A Low ? ✓ × High
35. Zhang et al54 ✓ ? ✓ ✓ Unclear × ✓ × High
36. Zuithoff et al47 ✓ ✓ ? ? Unclear ? ✓ ✓ Unclear
N/A, not applicable; PHQ-9, Patient Health Questionnaire-9.✓,criterion met;  ✗, criterion not met; ? ,insuficient information to code whether criterion met.
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Figure 1 Patient Health Questionnaire-9 algorithm scoring method summary receiver operating characteristic plot for the 
diagnosis of major depressive disorder in allegiant studies (panel A) and non-allegiant studies (panel B). Pooled sensitivity and 
speciicity estimates using a bivariate meta-analysis. HSROC, hierarchical receiver operating characteristic.
case-control design, avoid inappropriate exclusions). In 
the index test domain, the proportion of studies reporting 
that the PHQ-9 was conducted blind to the reference 
test was comparable between the two groups. There 
were differences in this domain for those studies using 
a translated version of the test. All non-English allegiant 
studies (5/5) used an appropriately translated version of 
the PHQ-9, whereas just over a half of the non-allegiant 
studies reported this (55%, 6/11). However, the majority 
of both sets of studies did not report details of psycho-
metric properties of the translated version. For the refer-
ence test domain, nearly all studies in both groups were 
rated as using a reference test that would correctly clas-
sify the condition. While most allegiant studies reported 
that the reference test was interpreted blind to the PHQ-9 
score (86%, 6/7), this was reported in only 60% (12/20) 
of the non-allegiant studies.
The two sets of studies that used translated versions 
of the reference test were broadly comparable. There 
was a slight indication that the allegiant studies were 
more likely to use an appropriately translated version 
of the reference test and report data on the psycho-
metric properties of the translated version, although 
the numbers for the translated comparison are very 
low. There were, however, some more notable differ-
ences on the flow and timing domain. Most allegiant 
studies ensured that the time between the index and 
reference test was under 2 weeks (86%, 6/7) in compar-
ison to 70% (14/20) of the non-allegiant studies. More 
allegiant studies met the criterion for ‘all participants 
included in the analysis’ (57%, 4/7) than non-allegiant 
studies (25%).
Summed items scoring method (cut-off point 10 or above)
Descriptive characteristics
Table 2 presents the sample characteristics of the 31 
PHQ-9 validation studies that reported the psychometric 
properties of the PHQ-9 at cut-off point 10 or above. 
Five of these studies were coauthored by the original 
developers of the instrument or acknowledged collabo-
ration12 23 26 49 or were coauthored by the first author of 
a previous study that had also been coauthored by one 
of the developers.28 Twenty-six studies were conducted by 
independent researchers.
Three (60%, 3/5) allegiant studies26 28 49 and 11 
non-allegiant studies (42%, 11/26)30–32 34 37 38 50–54 were 
conducted in hospital settings.
Three (60%, 3/5) allegiant studies12 26 49 and 13 non-al-
legiant studies (13/26)30 37 38 42 48 51–53 55–59 were conducted 
in English.
The mean prevalence of MDD in the allegiant group 
was 13.2% (range 6.1%–33.5%) and in the non-alle-
giant group was 16.1% (range 2.5%–43.2%). The mean 
age of patients in the allegiant group studies was 48.1 
(range 41.9–61.0) and in the 26 non-allegiant studies 
that reported these data was 49.1 (range 23.0–78.0). 
The percentage of females in the allegiant studies that 
reported these data12 23 26 28 was 56.3% (range 28.6%–
67.8%) and in the non-allegiant group was 64.9% (range 
12%–100%).
Three allegiant studies used the self-reported mode 
of administration and two of them did not specify how 
the PHQ-9 was administered. In nine non-allegiant 
studies (34%, 9/26), the PHQ-9 was administered by the 
researcher.30–32 48 56 58–61 All allegiant studies used SCID as 
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a gold standard; the non-allegiant studies used a wider 
range of gold standards including SCAN, CIDI, MINI, 
CIS-R, C-DIS, although the SCID was used in half of the 
studies (50%, 13/26 studies).
Three allegiant studies (60%) did not include a conflict 
of interest statement.12 23 49 Two of these studies12 23 
acknowledged funding from Pfizer. None of the allegiant 
studies acknowledged collaboration or authorship of one 
of the developers of the PHQ-9.
Of the non-allegiant studies, 13 (42%) did not include 
a conflict of interest statement.30–32 37 42 46 48 53 55 60 62–64 
Similar to the algorithm studies, the newer studies were 
more likely to include a conflict of interest statement. 
Funding was acknowledged by most studies (27/31) and 
most received funding from academic and/or health 
research institutions. One study57 acknowledged that the 
last author involved in the development of one of the 
instruments (CORE-OM), ‘but does not gain financially 
from its use’. One study51 acknowledged funding from 
industry, AHA Pharmaceuticals Roundtable, but stated 
that ‘the funding organisations had no role in the design 
or conduct of the study, collection, management, anal-
ysis or interpretation of data; or preparation, review or 
approval of the manuscript. Fine et al. disclosed that the 
last author had financial and consulting interests (Pfizer 
was not cited as one of them).56
Diagnostic test accuracy
Pooled sensitivity of allegiant studies was 0.87 (95% CI 
0.77 to 0.93), pooled specificity was 0.87 (95% CI 0.76 
to 0.94) and the pooled DOR was 49.31 (95% CI 25.74 
to 94.48)—see table 5. Heterogeneity was moderate 
(I²=55.1%). Figure 2 represents the sROCs for this group.
Pooled sensitivity of non-allegiant studies was 0.76 (95% 
CI 0.67 to 0.83), pooled specificity was 0.88 (95% CI 0.85 
to 0.91) and the pooled DOR was 24.96 (95% CI 14.81 
to 42.08), approximately half that of the allegiant studies 
(table 2). Heterogeneity was high at I²=81.5%. Figure 2 
represents the sROCs for this group.
The meta-regression for the studies using a cut-off point 
of 10 or above with allegiance status of the predictor 
showed that allegiance status was a significant predictor 
of the DOR (p=0.015) and explained 19.0% of observed 
heterogeneity.
Quality assessment
The results of the quality assessment using the QUADAS-2 
are given in table 4. For the patient selection domain, the 
two groups of studies were broadly comparable on two 
items (consecutive or random sample, avoid case-con-
trol design). However, all allegiant studies were rated as 
avoiding inappropriate exclusions (5/5) in contrast to 
58% (15/26) of the non-allegiant studies.
On the index test domain, there were a number of 
differences between the two groups of studies. More of 
the non-allegiant studies (81%, 21/26) reported that 
the PHQ-9 was interpreted blind to the reference test 
compared with 60% (3/5) of the allegiant studies. All 
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Figure 2 Patient Health Questionnaire-9 summed items scoring method at cut-off point 10 summary receiver operating 
characteristic plot for diagnosis of major depressive disorder in allegiant studies (panel A) and non-allegiant studies (panel B). 
Pooled sensitivity and speciicity using a bivariate meta-analysis. HSROC, hierarchical receiver operating characteristic.
(5/5) allegiant studies were rated as prespecifying the 
threshold on the PHQ-9 compared with 73% (19/26) 
of the non-allegiant studies. The two sets of studies were 
broadly comparable in terms of two items from the refer-
ence test domain (correctly classify target condition, refer-
ence test interpreted blind). Only one allegiant study used 
a translated version of the index test or reference test, 
so it is not possible to comment on differences between 
the two sets of studies in terms of these items from the 
index or reference test domains. For the flow and timing 
domain, the two groups of studies were broadly compa-
rable for two of the criteria (interval of 2 weeks or less, all 
participants receive same reference test). However, fewer 
than half of the non-allegiant studies met the criterion for 
‘all participants included in the analysis’ (42%, 11/26), 
whereas all allegiant studies met this criterion.
DISCUSSION
This is to our knowledge the first systematic examination 
of a possible ‘allegiance’ or authorship effect in the vali-
dation of screening or case-finding psychological instru-
ment for a common mental health disorder. We reviewed 
diagnostic validation studies of the PHQ-9, a widely used 
depression screening instrument. We found that allegiant 
studies reported higher sensitivity paired with similar 
specificity compared with non-allegiant studies. When 
entered as a covariate in meta-regression analyses, alle-
giance status was predictive of variation in the DOR for 
both the algorithm scoring method and the summed-
item scoring method at a cut-off point of 10 or above.
Previous research has proposed several possible expla-
nations for the allegiance effect.9–11 One possibility is the 
advertent bias that may serve to inflate the performance 
of a test when evaluated by those who have developed it. 
However, before concluding that the differences are due 
to this, it is important to explore and rule out alternative 
explanations. First, it is possible that any observed differ-
ences are a result of differences in study characteristics of 
the two sets of studies (eg, setting, clinical population). 
Second, differences in the methodological quality of the 
studies may also account for any differences. These possi-
bilities are examined below.
Difference in study characteristics as potential alternative 
explanations
The two sets of studies were broadly comparable in terms 
of gender and the prevalence of depression, so these vari-
ables are unlikely to offer an explanation for the differ-
ences. While there were some indications from both sets 
of comparisons that the PHQ-9 may have been research-
er-administered more often in the independent studies, 
it is not immediately clear how this would lead to lowered 
diagnostic performance.
The diagnostic meta-analyses of the PHQ-913 14 have 
shown that the sensitivity and DOR of the PHQ-9 tends 
to be lower in hospital settings for both algorithm and 
summed-item scoring methods. While the fact that 
proportionally more non-allegiant algorithm studies were 
conducted in secondary care could explain the lower 
sensitivity and DOR values in the algorithm studies, in 
the studies that reported the cut-off point of or above this 
would not be the case as proportionally more allegiant 
studies were conducted in hospital settings.
Similarly, differences in the proportions of studies using 
translated versions of the PHQ-9 are also unlikely to offer 
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an obvious explanation of the difference in diagnostic 
performance, because in the algorithm set of studies 
more of the allegiant studies used a translated version of 
the test, but the proportions were in the opposite direc-
tion for the studies using a cut-off of 10 or above. We 
tested this by carrying out a sensitivity analysis restricting 
the sample to English studies and studies with adequate 
translation. The allegiance effect was still predictive of 
DOR variation between allegiance and non-allegiance 
studies variation in both algorithm (p=0.00) and summed 
item scoring at cut-off point of 10 meta-analyses (p=0.02).
A similar conclusion is also likely to apply to the age 
of the samples. There were more older adults studies in 
the non-allegiant than allegiant studies in the algorithm 
comparison. Depression could be more difficult to iden-
tify in older adults due to physical comorbidities that 
may present with similar symptomatology to depression 
and could account for the lower diagnostic performance 
in the non-allegiant studies. However, the non-allegiant 
samples in the studies that reported the psychometric 
properties at cut-off point 10 or above had younger 
samples than the allegiant studies, so this would not 
support this interpretation.
The SCID was used as the gold standard in nearly all 
allegiant studies. The fact that some non-allegiant studies 
used other gold standards could potentially explain the 
poorer psychometric properties of the PHQ-9 in these 
studies. The SCID is often regarded as the most valid of 
the available semi-structured interviews used in depres-
sion diagnostic validity studies as the reference standard. 
If we assume that this is the case and, furthermore, that 
the PHQ-9 is an accurate method of screening for depres-
sion, then the PHQ-9 may be more likely to agree with the 
SCID than other reference standards. However, when we 
carried out a sensitivity analysis restricting the sample to 
SCID-only studies, the allegiance effect was still predictive 
of DOR variation between allegiance and non-allegiance 
studies variation in both algorithm (p=0.01) and summed 
item scoring at cut-off point of 10 reviews (p=0.02).
Differences in methodological quality as potential alternative 
explanations
The quality of the studies was evaluated using the 
QUADAS-2. Although there were several potential meth-
odological differences between the two groups of studies 
from the algorithm papers, not all of these offer obvious 
explanations of the observed differences and some are 
unlikely as explanations. For example, more allegiant 
studies ensured that the reference test was interpreted 
blind to the index test. This is unlikely to account for 
the observed differences, because a lack of blinding is 
typically associated with artificially increased diagnostic 
performance, which is in the opposite direction to the 
pattern of results observed here. The impact of some 
other differences is less clear-cut. For example, a higher 
number of the non-allegiant studies met the criterion for 
consecutive referrals. For this to provide an explanation 
of the observed differences, the non-consecutive nature 
of the referrals in the studies by those who had developed 
the PHQ-9 would need to have led to the overinclusion of 
true positives or underinclusion of false negatives given 
that these studies tended to report higher sensitivity 
relative to the non-allegiant studies (and vice versa for 
the independent studies). It is not immediately obvious 
how this would occur. The allegiant studies were more 
likely to have met the criterion of ‘included all partici-
pants in the analysis’. It is possible that the greater loss 
of participants from the non-allegiant studies may have 
artificially reduced the observed diagnostic accuracy, 
although, again, it is not immediately obvious how this 
would have affected the true positive and false negative 
rates. Although there is not an obvious explanation of 
how these differences in methodological quality could 
account for the observed differences in diagnostic perfor-
mance, it is important to recognise that they cannot on 
that basis be ruled out.
There are, however, two differences in methodolog-
ical quality among the algorithm studies that are clearer 
potential alternative explanations. The higher rate of 
appropriate translations among the allegiant studies is 
potentially important, because lower diagnostic estimates 
may be expected from studies that have poorly translated 
versions of the index test. In the flow and timing domain, 
more allegiant studies ensured that there was a less than 
2-week interval between the index and reference test. 
This is consistent with lower diagnostic performance in 
the non-allegiant studies: as the interval increases it is 
likely that depression status may change and this would 
lead to lower levels of agreement between the index test 
and the reference test.
There were also differences on some quality assessment 
items between the two sets of studies in the summed item 
scoring method comparison. The threshold was reported 
as prespecified in all allegiant studies in contrast to 
approximately three-quarters of the non-allegiant studies. 
On the face of it, this is unlikely to explain the observed 
differences, because the use of a prespecified cut-off point 
is likely to be associated with lower not higher diagnostic 
test performance. One possibility, however, is that studies 
that performed poorly at this cut-off point were less likely 
to be reported by those who had developed the measure. 
As discussed in more detail in the 'Limitations' section, we 
were unable to explore this possibility through the use of 
formal tests for publication bias.
All allegiant studies avoided inappropriate exclusions 
compared with approximately half of the non-allegiant 
studies. While this is a potential alternative explanation 
of the differences, it is not immediately obvious how this 
would explain the differences in diagnostic performance 
between the two sets of studies. Fewer than half of the 
non-allegiant studies met the criterion for ‘all partici-
pants included in the analysis’, in contrast to all of the 
allegiant studies met this criterion, but again this differ-
ence should usually work against the inclusive studies, not 
those excluding cases. More of the non-allegiant studies 
reported that the PHQ-9 was interpreted blind to the 
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reference test. This does offer a potential explanation, 
because the absence of blinding may artificially inflate 
diagnostic accuracy.
LIMITATIONS
The results of this review need to be viewed in light of 
the limitations of the primary studies that contributed 
to the review and the review itself. An important consid-
eration is to establish whether any observed differences 
between the diagnostic performance of the non-al-
legiant and allegiant studies are better accounted for 
by study characteristic or methodological differences. 
Caution, however, is needed in interpreting any differ-
ences, because of the small number of allegiant studies 
in both the algorithm and cut-off 10 or above compari-
sons. The small number of allegiant studies also meant 
that we were also unable to explore the potential role 
of publication bias in the non-allegiant and allegiant 
studies. At least 10 studies are required to use standard 
methods of examining publication bias, but the number 
of allegiant studies in both the algorithm and cut-off 
10 or above comparisons were fewer than this. Papers 
published from August 2013 onwards are not covered 
in the literature search used and so it potentially misses 
some more recent studies that would be eligible for 
inclusion, although it is unlikely that many, if any, new 
allegiant studies have been published since.
CONCLUSIONS AND IMPLICATIONS FOR FURTHER RESEARCH
The aims of the review was to investigate whether an 
allegiance effect is found that leads to an increased 
diagnostic performance in diagnostic validation studies 
that were conducted by teams connected to the orig-
inal developers of the PHQ-9. Our analyses showed 
that diagnostic studies conducted by independent/
non-allegiant researchers had lower sensitivity paired 
with similar specificity compared with studies that were 
classified as allegiant. This conclusion held for both the 
algorithm and cut-off 10 or above studies. We explored 
a range of possible alternative explanations for the 
observed allegiance effect including both differences 
in study characteristics and study quality. A number of 
potential differences were found, although for some of 
these it is not clear how they would necessarily account 
for the observed differences. However, there were a 
number of differences that offered potential alternative 
explanations unconnected to allegiance effects. In the 
algorithm studies, the studies rated as allegiant were 
also more likely to use an appropriate translation of 
the PHQ-9 and were also more likely to ensure that the 
index and reference test were conducted within 2 weeks 
of each other, both of which may be associated with an 
improvement in observed diagnostic performance of an 
instrument. The majority of studies in both meta-anal-
yses did not provide clear statements about potential 
conflict of interest and/or funding; however, the newer 
studies were more likely to provide such statements, 
which may reflect increasing transparency in this area 
of research.
We cannot, therefore, conclude that allegiance effects 
are present in studies examining the diagnostic perfor-
mance of the PHQ-9; but nor can we rule them out. 
Conflicts of interest are an important area of investiga-
tion in medical and behavioural research, particularly 
due to concerns about trial results being influenced by 
industry sponsorship. Future diagnostic validity in this 
area should as a matter of routine present clear state-
ments about potential conflicts of interest and funding, 
particularly relating to the development of the instru-
ment under evaluation. Future meta-analyses of diag-
nostic validation studies of psychological measures 
should routinely evaluate the impact of researcher 
allegiance in the primary studies examined in the 
meta-analysis.
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